Despite recent advances in the management of colorectal cancer, metastatic disease
remains challenging, and patients are rarely cured. However, a better understanding of the …

Colon cancer is the third most common cancer worldwide. Most colorectal cancer
occurrences are sporadic, not related to genetic predisposition or family history; however, 20 …

Background In the KEYNOTE-177 study, pembrolizumab monotherapy provided statistically
significant and clinically meaningful improvements in progression-free survival versus …

Colorectal cancer (CRC) has the second highest mortality rate among all cancers
worldwide. Surgery, chemotherapy, radiotherapy, molecular targeting and other treatment …

The epidermal growth factor receptor (EGFR) is one of most potent oncogenes that are
commonly altered in cancers. As a receptor tyrosine kinase, EGFR's kinase activity has been …

As glutamine plays a central role in cancer metabolism, inhibition of glutaminolysis has
become an ideal anticancer therapeutic target. However, glutaminolysis inhibition leads to …

Epithelial growth factor receptor (EGFR), a transmembrane receptor on the cell surface,
carries extracellular messages into the cell and alters the activity of the nucleus through …

Epidermal growth factor receptor (EGFR) inhibitors were among the first type of targeted
agents discovered in cancer and currently constitute the standard of care for a wide range of …

Colorectal cancer is the second most common cancer, representing 13% of all diagnosed
cancers. Cetuximab is a recombinant chimeric monoclonal IgG1 antibody and epidermal …

Complex multicellular organisms have evolved sophisticated mechanisms to rapidly resolve
epithelial injuries. Epithelial integrity is critical to maintaining internal homeostasis. An …